Cybrexa Therapeutics Inc

Meet Cybrexa’s leadership team built on deep experience in oncology drug development, clinical trials, and company growth. Together, we are developing the next generation of cancer therapeutics and advancing the future of cancer treatment. bit.ly/4hbRVUm

Cybrexa’s alphalex™- enabled peptide-drug conjugates bypass traditional therapy limits by targeting universal tumor biology. Our antigen-agnostic approach means more patients with cancer may benefit from treatment, regardless of specific tumor markers. bit.ly/3CobYzO

Cybrexa Therapeutics presented new preclinical data at #ESMOTAT25 showing alphalex™ peptide-drug conjugates achieved robust efficacy across multiple tumor models, both as monotherapy and in combination with standard treatments. Read the full results here: bit.ly/3FgoSkf

Cybrexa will present new preclinical findings at #ESMOTAT25 on the potential of alphalex™ peptide-drug conjugates to achieve tumor-selective delivery while minimizing off-target effects. 📅 March 3 | ⏰ 5:15-6:15 PM CET | 🎤 Vishwas Paralkar, Ph.D. bit.ly/41uXCHv

In a robust Phase 1 trial, our lead clinical-stage program, CBX-12, showed compelling safety & efficacy across six tumor types. With activity confirmed, even in heavily pretreated patients, we are advancing CBX-12 into Phase 2 trials. bit.ly/4ggu58J #biotech

Our alphalex™ tumor-targeting peptide platform leverages the acidic microenvironment found in all solid tumors, enabling precise delivery of potent therapies where they’re needed most. Explore our science: bit.ly/3CobYzO #biotech

Just announced: The first patient has been dosed with CBX-12 in a Phase 2 trial in women with platinum-resistant or refractory #ovariancancer who are naïve to TOP1-targeted therapies. Learn more at bit.ly/4dJDq7S. #biotech #oncology #clinicaltrials

We announced final results from our Phase 1 study of CBX-12 in advanced solid tumors, which showed broad activity across 6 tumor types, including strong response rates in TOP1-naive patients with ovarian and breast #cancer. Read more: bit.ly/3B3gR05 #ESMO24 #biotech

We look forward to presenting full results from our Phase 1 study of peptide drug conjugate CBX-12 in advanced solid tumors at @myESMO. Join us at 12pm CET on Sept 14 to learn more: bit.ly/3ZkTk4Y #oncology #ESMO24 #biotech

#Cybrexa is revolutionizing #cancertherapeutics with its innovative alphalex™ platform, aiming to deliver drugs directly into cancer cells. Stay tuned for exciting clinical updates. bit.ly/3yCiugx. #peptidedrugconjugates #oncology

#DYK, Cybrexa's scientists are pioneering #cancertherapeutics to target tumors & spare healthy tissue? Our approach aims to enhance current therapies & pave the way for new ones. 👉 bit.ly/3yB7osv. #drugdiscovery #smallmolecules #peptidedrugconjugates #WeAreCybrexa

Happy #IndependenceDay! Today we are celebrating the freedom made possible by our brave heroes. #FourthofJuly #WeAreCybrexa

#NEWS: Cybrexa Therapeutics today announced the appt. of former founding Alnylam CEO, @JMaraganore, as Strategic Advisor to the Exec. Leadership Team. Full release: bit.ly/4eAIIEa. #drugdiscovery #smallmolecules #peptidedrugconjugates #CTBiotech #WeAreCybrexa

#DYK: #Cybrexa & most of our team are HQ’d in #CT, but some of us live in FL, GA, MA, NH, NJ, RI & TX. Despite the distance, Cybrexa’s commitment to raising awareness for various cancers unites our team. Last month, we wore teal ribbons on #WorldOvarianCancerDay. Check us out 👇!

On this #MemorialDay, we remember those who gave their lives for our freedom. We wish everyone a safe & meaningful Memorial Day weekend. #MDW24

At #Cybrexa, we're working to revolutionize #cancertherapeutics by leveraging our alphalex™ technology to develop novel & innovative anti-cancer agents. bit.ly/3yCiugx. #drugdiscovery #smallmolecules #peptidedrugconjugates

Join us at the ADC Payload Summit in Boston next week for a discussion on #Cybrexa's tumor-selective alphalex™ platform by our CSO Vish Paralkar. Check out the conference agenda here 👉: bit.ly/43W8RZj.

Today is #WorldOvarianCancerDay. Early detection is key. Check out the resources below to learn more. Let's spread awareness and make a difference in the fight against #ovariancancer. #earlydetection #getscreened

Meet Lindsey Clapes, Office Manager at #Cybrexa. W/ 10+ yrs exp in biotech/pharma, Lindsey oversees the travel program, organizes team events, leads community outreach & keeps track of the boss. She enjoys the startup environment & progression of science. #EmployeeSpotlight

Happy #WorldLaboratoryDay! At Cybrexa, our lab team is working hard to develop new #cancertherapeutics with the potential to improve pts' lives. Learn about our mission & the incredible work we are doing to transform the future of #oncolgy 👉 bit.ly/4a3hd3n.